This 5-question survey of primary care physicians (24 family practice and 18 internal medicine) evaluates the impact of the FDA’s warning about diabetic ketoacidosis with SGLT2 inhibitors in Type 2 diabetes. The survey looks at level of concern, change in usage, and projections if the rate of DKA is at various levels (which can be compared to JNJ's just published rates from Invokana's clinical program). The latter identifies the inflection point at which respondents would start to dramatically reduce usage of these agents. We also look at projected usage of SGLT2/DPP4 inhibitor fixed dose combinations (FDCs).

2015 Post- ADA Report.

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2015 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

To purchase this survey, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.